File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1186/s12879-019-4181-2
- Scopus: eid_2-s2.0-85070084547
- PMID: 31357951
- WOS: WOS:000477828700007
Supplementary
- Citations:
- Appears in Collections:
Article: Clinical characteristics and outcomes during a severe influenza season in China during 2017-2018
Title | Clinical characteristics and outcomes during a severe influenza season in China during 2017-2018 |
---|---|
Authors | |
Keywords | In-hospital fatality rates The 2017-2018 influenza Antiviral therapy Subtype Clinical characteristics |
Issue Date | 2019 |
Citation | BMC Infectious Diseases, 2019, v. 19, n. 1, article no. 668 How to Cite? |
Abstract | © 2019 The Author(s). Background: A severe seasonal influenza epidemic was observed during 2017-2018 in China, prompting questions on clinical characteristics and outcomes of severe cases with influenza. Methods: We retrospectively collected clinical data and outcomes of laboratory-confirmed hospitalized patients (severe to critical) during Jan-2011 to Feb-2018 from five hospitals, followed by a systematic analysis of cases from 2017 to 2018 (n = 289) and all previous epidemics during 2011-2017 (n = 169). Results: In-hospital fatality was over 5-folds higher during the 2017-2018 (p < 0.01) in which 19 patients died (6.6%), whereas only 2 mortalities (1.2%) were observed during 2011-2017. Of the 289 hospitalized in 2017-2018, 153 were confirmed with influenza B virus, 110 with A/H1N1pdm09, and 26 A/H3N2, whereas A/H1N1pdm09 was the predominant cause of hospitalization in previous seasons combined (45%). Fatal cases in 2017-2018 were exclusively associated with either influenza B or A/H1N1pdm09. Our results show that a significant lower proportion of patients aged 14 or greater were treated with oseltamivir, during the 2017-2018 epidemic, and exhibited higher levels of clinical severity. Conclusions: In-hospital fatality rate might be significantly higher in the 2017-2018 season in China. A sufficient supply of oseltamivir and antiviral therapy within 48 h from onset could reduce fatality rates. |
Persistent Identifier | http://hdl.handle.net/10722/288952 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fu, Xiaofang | - |
dc.contributor.author | Zhou, Yuqing | - |
dc.contributor.author | Wu, Jie | - |
dc.contributor.author | Liu, Xiaoxiao | - |
dc.contributor.author | Ding, Cheng | - |
dc.contributor.author | Huang, Chenyang | - |
dc.contributor.author | Zheng, Shufa | - |
dc.contributor.author | Vijaykrishna, Dhanasekaran | - |
dc.contributor.author | Chen, Yu | - |
dc.contributor.author | Li, Lanjuan | - |
dc.contributor.author | Yang, Shigui | - |
dc.date.accessioned | 2020-10-12T08:06:18Z | - |
dc.date.available | 2020-10-12T08:06:18Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | BMC Infectious Diseases, 2019, v. 19, n. 1, article no. 668 | - |
dc.identifier.uri | http://hdl.handle.net/10722/288952 | - |
dc.description.abstract | © 2019 The Author(s). Background: A severe seasonal influenza epidemic was observed during 2017-2018 in China, prompting questions on clinical characteristics and outcomes of severe cases with influenza. Methods: We retrospectively collected clinical data and outcomes of laboratory-confirmed hospitalized patients (severe to critical) during Jan-2011 to Feb-2018 from five hospitals, followed by a systematic analysis of cases from 2017 to 2018 (n = 289) and all previous epidemics during 2011-2017 (n = 169). Results: In-hospital fatality was over 5-folds higher during the 2017-2018 (p < 0.01) in which 19 patients died (6.6%), whereas only 2 mortalities (1.2%) were observed during 2011-2017. Of the 289 hospitalized in 2017-2018, 153 were confirmed with influenza B virus, 110 with A/H1N1pdm09, and 26 A/H3N2, whereas A/H1N1pdm09 was the predominant cause of hospitalization in previous seasons combined (45%). Fatal cases in 2017-2018 were exclusively associated with either influenza B or A/H1N1pdm09. Our results show that a significant lower proportion of patients aged 14 or greater were treated with oseltamivir, during the 2017-2018 epidemic, and exhibited higher levels of clinical severity. Conclusions: In-hospital fatality rate might be significantly higher in the 2017-2018 season in China. A sufficient supply of oseltamivir and antiviral therapy within 48 h from onset could reduce fatality rates. | - |
dc.language | eng | - |
dc.relation.ispartof | BMC Infectious Diseases | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | In-hospital fatality rates | - |
dc.subject | The 2017-2018 influenza | - |
dc.subject | Antiviral therapy | - |
dc.subject | Subtype | - |
dc.subject | Clinical characteristics | - |
dc.title | Clinical characteristics and outcomes during a severe influenza season in China during 2017-2018 | - |
dc.type | Article | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1186/s12879-019-4181-2 | - |
dc.identifier.pmid | 31357951 | - |
dc.identifier.pmcid | PMC6664535 | - |
dc.identifier.scopus | eid_2-s2.0-85070084547 | - |
dc.identifier.volume | 19 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | article no. 668 | - |
dc.identifier.epage | article no. 668 | - |
dc.identifier.eissn | 1471-2334 | - |
dc.identifier.isi | WOS:000477828700007 | - |
dc.identifier.issnl | 1471-2334 | - |